Delivery Order SPE2DB20D3111-SPE2DB26FA5PG
- Not listed
- The Defense Logistics Agency awarded a $3,449 delivery order to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes. This firm fixed-price contract, with an ultimate completion date of November 3, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract carries no set-aside designation and was competitively awarded. Performance will occur at...
- The Defense Logistics Agency (DLA) awarded a $3,449.50 delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on September 12, 2025, with completion scheduled for September 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger federal contract vehicle. The order will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes valued at $6,899.00, with completion due by August 1, 2025. This non-set-aside, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $10,348.50 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on August 11, 2025, with completion expected by August 12, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The vaccine product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $13,796 delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on October 28, 2025, with completion scheduled for October 29, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The vaccine product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $4,557.96 delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be performed at the vendor's location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,694.07 firm fixed price delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on August 29, 2025, with completion targeted for September 2, 2025. This non-set-aside delivery order represents a small-value transaction under AmerisourceBergen's larger pharmaceutical supply contract with DLA. The product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $2,759.60 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for TYPHIM VI 25 MCG/0.5 ML syringes. This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 25, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for TYPHIM VI 25 MCG/0.5 ML vaccine syringes valued at $8,442.90 under a firm fixed-price contract with completion scheduled for September 3, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The prime...
- The Defense Logistics Agency awarded a $1,724.75 firm fixed price delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes, with an ultimate completion date of August 5, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in...
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB26FA5PGDelivery Order
The Defense Logistics Agency awarded a $5,518.40 delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on October 28, 2025, with completion scheduled for October 29, 2025. This non-set-aside contract utilized firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform this delivery from the same location. This delivery order exemplifies AmerisourceBergen's critical role as a federal medical supplier, leveraging its $999.999 billion IDC valued through December 2026 to supply vaccines and pharmaceutical products to military healthcare systems. As a major pharmaceutical distributor with extensive federal procurement experience, AmerisourceBergen routinely fulfills competitively awarded orders across DLA's Medical Supply Chain, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities with branded and generic medications, vaccines, medical devices, and specialty pharmaceuticals across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 10/28/25 |